<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547520</url>
  </required_header>
  <id_info>
    <org_study_id>DalinTCGH-hsieh-02</org_study_id>
    <nct_id>NCT01547520</nct_id>
  </id_info>
  <brief_title>Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy</brief_title>
  <official_title>Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy, a Double-blind, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalin Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dalin Tzu Chi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Upper endoscopy is uncomfortable for most patients. Meperidine has both sedative and
      analgesic effects, so its use may be helpful for patients receiving upper endoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unsedated esophagogastroduodenoscopy (EGD) is a useful tool for upper gastrointestinal tract
      examination and therapy, but it is uncomfortable for many patients. Meperidine has been
      widely used in colonoscopic examination for many years; however, its use in EGD has not been
      completely evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>discomfort score during esophageal intubation</measure>
    <time_frame>9 months</time_frame>
    <description>patient self-reported discomfort score during esophageal intubation, assessed with a 0 to 10 visual analog scale (VAS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient and endoscopist satisfaction score</measure>
    <time_frame>9 months</time_frame>
    <description>patient and endoscopist satisfaction with the procedure, score 0(not satisfied at all)-10 (very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient tolerance of the procedure</measure>
    <time_frame>9 months</time_frame>
    <description>patolerace of the EGD, evaluate by the endoscopist, score 0 (best tolerance)-10 (very poor tolerance, the procedure could not be completed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopist perception of patient tolerance ,</measure>
    <time_frame>9 months</time_frame>
    <description>endoscopist evaluation of patient tolerance during EGD, score 0 (best tolerance)- 10 (worst tolerance, the procedure can not be completed)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Esophagogastroduodenoscopy</condition>
  <arm_group>
    <arm_group_label>meperidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg of meperidine is injected intramuscularly before EGD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo was given intramuscularly before EGD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <description>intramuscular, 25 mg, 5 to 10 minutes before EGD</description>
    <arm_group_label>meperidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing diagnostic upper endoscopy in our endoscopic room were enrolled.

        Exclusion Criteria:

          -  A therapeutic upper endoscopic procedure, sedated endoscopy, contraindication to
             Buscopan (hyoscine N-butylbromide)

          -  Allergy to meperidine

          -  American Society of Anesthesiology (ASA) risk Class 3 or higher

          -  Renal failure

          -  Decompensated cirrhosis

          -  Aged less than 20 years or more than 65 years

          -  Pregnancy

          -  Refusal to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Hsi Hsieh, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalin Tzu Chi General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dalin Tzu Chi General Hospital</name>
      <address>
        <city>Chia-Yi</city>
        <zip>622</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Abraham NS, Fallone CA, Mayrand S, Huang J, Wieczorek P, Barkun AN. Sedation versus no sedation in the performance of diagnostic upper gastrointestinal endoscopy: a Canadian randomized controlled cost-outcome study. Am J Gastroenterol. 2004 Sep;99(9):1692-9.</citation>
    <PMID>15330904</PMID>
  </reference>
  <reference>
    <citation>Ishido S, Kinoshita Y, Kitajima N, Itoh T, Nishiyama K, Tojo M, Yano T, Inatome T, Fukuzaki H, Chiba T. Fentanyl for sedation during upper gastrointestinal endoscopy. Gastrointest Endosc. 1992 Nov-Dec;38(6):689-92.</citation>
    <PMID>1473671</PMID>
  </reference>
  <reference>
    <citation>Laluna L, Allen ML, Dimarino AJ Jr. The comparison of midazolam and topical lidocaine spray versus the combination of midazolam, meperidine, and topical lidocaine spray to sedate patients for upper endoscopy. Gastrointest Endosc. 2001 Mar;53(3):289-93.</citation>
    <PMID>11231385</PMID>
  </reference>
  <reference>
    <citation>Diab FH, King PD, Barthel JS, Marshall JB. Efficacy and safety of combined meperidine and midazolam for EGD sedation compared with midazolam alone. Am J Gastroenterol. 1996 Jun;91(6):1120-5.</citation>
    <PMID>8651156</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meperidine</keyword>
  <keyword>esophagogastroduodenoscopy</keyword>
  <keyword>unsedated</keyword>
  <keyword>minimal sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Meperidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 2, 2012</submitted>
    <returned>April 25, 2012</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

